The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

First, the researchers compared 1,857 patients with severe AD who used dupilumab without any other systemic therapy (average age at dupilumab prescription, 28.54 years; 51.59% female; 49.81% white ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin ...

TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has ...

USA: A recent case report published in The Open Dermatology Journal has brought attention to the successful use of ...

Dupilumab use in asthma is linked to higher lymphoma risk, especially T and NK cell types, but also shows reduced all-cause ...

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU) Regeneron Pharmaceuticals, Inc. Fri, Apr 18, 2025, 11:15 AM ...

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU) Provided by GlobeNewswire Apr 18, 2025, 3:15:32 PM ...